Samuelsson O, Pennert K, Andersson O, Berglund G, Hedner T, Persson B, Wedel H, Wilhelmsen L
Sahlgrenska Universitetssjukhuset/Sahlgrenska, Göteborg.
Lakartidningen. 1998 Mar 11;95(11):1120-3.
In an observational study designed to determine whether metabolic changes during long-term antihypertensive drug treatment are associated with an increased risk of coronary heart disease (CHD), 686 middle-aged hypertensive men recruited from a random population screening sample were followed up for 15 years. Antihypertensive treatment predominantly consisted of beta-adrenoceptor blockers and/or thiazide diuretics. CHD and diabetes mellitus were checked for at annual examinations. Time-dependent Cox regression analysis was used to determine correlation between the incidence of CHD and entry characteristics, the monitored serum levels of cholesterol and triglyceride concentrations and the development of diabetes mellitus. Univariate analysis showed the presence of diabetes mellitus a entry to the study and increased baseline serum concentrations of cholesterol and of triglycerides each to be a significant predictor of CHD, the respective relative risks (RR) being 2.12, 1.21 and 1.21. However, analysis of monitored levels of metabolic variables during follow-up showed only an increased serum cholesterol concentration to be significantly and independently associated with CHD (RR 1.07). Although serum triglyceride concentrations increased slightly during follow-up, they were unrelated to the incidence of CHD; nor was onset of diabetes mellitus during follow-up significantly associated with an increased risk of CHD (RR 1.48. Thus, the study showed the presence of metabolic disturbances such as diabetes mellitus and hyperlipidaemia before the start of antihypertensive treatment to be of positive predictive value in middle-aged hypertensive men, and an increase in the monitored serum cholesterol level to be an independent predictor of CHD, whereas neither drug-related diabetes nor an increase in the monitored serum triglyceride concentration seemed to be associated with the occurrence of CHD.
在一项旨在确定长期抗高血压药物治疗期间的代谢变化是否与冠心病(CHD)风险增加相关的观察性研究中,从随机人群筛查样本中招募的686名中年高血压男性被随访了15年。抗高血压治疗主要包括β-肾上腺素能受体阻滞剂和/或噻嗪类利尿剂。每年检查冠心病和糖尿病。采用时间依赖性Cox回归分析来确定冠心病发病率与入组特征、监测的血清胆固醇和甘油三酯浓度水平以及糖尿病的发生之间的相关性。单因素分析显示,研究入组时存在糖尿病以及基线血清胆固醇和甘油三酯浓度升高均是冠心病的重要预测因素,各自的相对风险(RR)分别为2.12、1.21和1.21。然而,对随访期间代谢变量监测水平的分析显示,只有血清胆固醇浓度升高与冠心病显著且独立相关(RR 1.07)。尽管随访期间血清甘油三酯浓度略有升高,但它们与冠心病发病率无关;随访期间糖尿病的发生也与冠心病风险增加无显著关联(RR 1.48)。因此,该研究表明,在抗高血压治疗开始前存在糖尿病和高脂血症等代谢紊乱在中年高血压男性中具有阳性预测价值,监测的血清胆固醇水平升高是冠心病的独立预测因素,而药物相关糖尿病和监测的血清甘油三酯浓度升高似乎均与冠心病的发生无关。